Fortress Biotech Inc Stock Price, News & Analysis

Journey Medical Corporation (NASDAQ: DERM) reported its Q1 2025 financial results, highlighting total net product revenues of $13.1 million, consistent with $13.0 million in Q1 2024. The company successfully launched Emrosi™, their new oral rosacea treatment, contributing $2.1 million in incremental revenue. The company's gross margin improved to 64% from 54% year-over-year.

Key financial metrics include a reduced net loss of $4.1 million ($0.18 per share) compared to $10.4 million ($0.53 per share) in Q1 2024. Cash position strengthened to $21.1 million as of March 31, 2025. The company reported no R&D costs in Q1 2025, down from $7.9 million in Q1 2024, while SG&A expenses increased by $2.1 million due to Emrosi launch activities.

Notable achievements include the publication of Emrosi's Phase 3 trial results in JAMA Dermatology, showing superiority over Oracea® and placebo, and its inclusion in the National Rosacea Society's Treatment Algorithms.

Checkpoint Therapeutics (NASDAQ: CKPT) announced its Q1 2025 financial results and significant corporate updates. The company achieved a major milestone with the FDA approval of UNLOXCYT™ (cosibelimab-ipdl) in December 2024, becoming the first and only PD-L1 blocking antibody approved for treating advanced cutaneous squamous cell carcinoma. In March 2025, Checkpoint entered into a merger agreement with Sun Pharmaceutical Industries, valued at up to $416 million, with the special stockholder meeting scheduled for May 28, 2025.

Financial highlights for Q1 2025 include: cash position increased to $33.0 million from $6.6 million in Q4 2024; R&D expenses decreased to $3.8 million from $8.5 million year-over-year; G&A expenses increased to $7.4 million from $2.5 million; and net loss was $11.2 million ($0.19 per share) compared to $10.9 million ($0.33 per share) in Q1 2024.

Journey Medical Corporation (NASDAQ: DERM), a commercial-stage pharmaceutical company focused on marketing FDA-approved dermatological treatments, has scheduled its first quarter 2025 financial results announcement for May 14, 2025, after U.S. market close.

The company will host a conference call and audio webcast at 4:30 p.m. ET on the same day. U.S. participants can dial 1-866-777-2509, while international callers should use 1-412-317-5413. The webcast will be accessible through Journey Medical's website and will remain available for approximately 30 days after the call.

Fortress Biotech (NASDAQ: FBIO), a biopharmaceutical company focused on acquiring and advancing assets for shareholder value through product revenue, equity holdings and dividend and royalty revenue, has announced its participation in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference on May 13, 2025.

The company's CEO, Lindsay A. Rosenwald, M.D., will participate in two sessions: a Fireside Chat from 2:00 PM to 2:30 PM ET, and a Panel Presentation titled "Development Stage Companies – Where Do Royalty and Tech Platform Plays Fit?" from 5:00 PM to 6:00 PM ET.

Journey Medical (NASDAQ: DERM) has promoted Ramsey Alloush from General Counsel to Chief Operating Officer (COO), while maintaining his General Counsel position. Alloush, who joined the company in 2020, brings over 15 years of pharmaceutical industry experience.

During his tenure at Journey Medical, Alloush has played a important role in navigating regulatory landscapes, managing financing transactions including the company's 2021 IPO, and overseeing acquisitions and licensing. His background includes experience at the Securities and Exchange Commission and Medicis Pharmaceuticals' Aesthetics Division.

The appointment comes at a strategic time as Journey Medical prepares for the launch of Emrosi™, a new dermatological treatment. The company focuses on marketing FDA-approved prescription pharmaceutical products for dermatological conditions.

Fortress Biotech (FBIO) reported significant developments for 2024, including two FDA approvals: Emrosi™ for rosacea treatment and UNLOXCYT™ for advanced skin cancer. The company's subsidiary Checkpoint Therapeutics is being acquired by Sun Pharma, expected to bring Fortress approximately $28 million at closing plus a 2.5% royalty on UNLOXCYT sales.

Key financial metrics for 2024 include consolidated net revenue of $57.7 million, down from $84.5 million in 2023. The company reported a net loss of $(55.9) million or $(2.69) per share, improved from $(68.7) million in 2023. Cash position stood at $57.3 million as of December 31, 2024.

Notable developments include FDA's acceptance of CUTX-101's New Drug Application for Menkes disease with a PDUFA date of September 30, 2025, and the commercial launch of Emrosi with first prescriptions filled.

Checkpoint Therapeutics (CKPT) announced significant developments in its 2024 financial results and corporate updates. The company secured FDA approval for UNLOXCYT™ (cosibelimab-ipdl), the first PD-L1 blocking antibody approved for treating advanced cutaneous squamous cell carcinoma. Additionally, CKPT entered into a merger agreement with Sun Pharmaceutical Industries valued at up to $416 million, expected to close in Q2 2025.

Financial highlights for 2024 include: Cash position increased to $6.6 million from $4.9 million in 2023, with an additional $38.1 million received post-year-end through warrant exercises. R&D expenses decreased to $36.2 million from $43.6 million, while G&A expenses increased to $20.1 million from $8.7 million. The company reported a net loss of $56.2 million ($1.42 per share) compared to $51.8 million ($3.17 per share) in 2023.

Journey Medical (DERM) reported its full-year 2024 financial results, with total revenues of $56.1 million, meeting all financial guidance targets. The company received FDA approval for Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for rosacea treatment in November 2024, with initial distribution and first prescriptions already underway.

Key financial metrics include:

• Product revenue decreased 8% to $55.1 million from $59.7 million in 2023
• Net loss of $(14.7) million, or $(0.72) per share, compared to $(3.9) million in 2023
• Adjusted EBITDA of $0.8 million
• Cash position of $20.3 million as of December 31, 2024

The company's Phase 3 clinical trial results for Emrosi were published in JAMA Dermatology, demonstrating successful achievement of co-primary and secondary endpoints. Full promotion is expected to begin in April 2025.

Journey Medical (NASDAQ: DERM) has announced the launch and first prescriptions of Emrosi™, a 40 mg Minocycline Hydrochloride Modified-Release Capsule treatment for inflammatory lesions of rosacea in adults. The medication, which received FDA approval in November 2024, is now available through specialty pharmacy chains.

Emrosi is the lowest-dose oral minocycline available, featuring a unique 10 mg immediate release and 30 mg extended release formulation. Clinical trials demonstrated superior efficacy compared to Oracea® and placebo while maintaining a comparable safety profile. The most common adverse reaction reported was dyspepsia, occurring in ≥1% of subjects.